News in 2015

Viewing Page 5 of 7 | Showing Results 41 - 50 of 62

Swedish and Nativis Partner in First Human Clinical Trial to Disrupt Cancer Cell Division

April 29, 2015

Swedish’s Ben & Catherine Ivy Center for Advanced Brain Tumor Treatment launches new clinical trial to treat brain cancer with the Nativis Voyager Radio Frequency Energy (RFE) Medical Device

SEATTLE, April 29, 2015 – The Swedish Neuroscience Institute’s Ben & Catherine Ivy Center for Advanced Brain Tumor Treatment today announced a new clinical trial for treating brain cancer. The trial (ID no. NCT02296580 – “A Feasibility Study of the Nativis Voyager System in Patients with Recurrent Glioblastoma Multiforme”), sponsored by Nativis, Inc. in Seattle – will investigate the safety and efficacy of the Nativis Voyager RFE medical device in humans. The device has shown promise in preclinical studies.

"This technology has been in development for more than a decade," said John Butters, Chairman, President and CEO of Nativis." We are proud to be partnering in this clinical trial with Dr. Charles Cobbs, and the world-class teams of Neurosurgeons and Neuro-oncologists at Swedish."

Pacific Northwest Kidney 'Paired' Exchange Program Performs its First Three-Way Kidney Transplant

April 27, 2015

Swedish and Oregon Health & Science University celebrate historic milestone in honor of National Donate Life Month

SEATTLE, April 27, 2015 – Organ donor networks are turning to local communities to save lives through multiple organ exchanges. Swedish and Oregon Health & Science University (OHSU) today announced the Pacific Northwest Regional Kidney Paired Exchange Program’s first three-way kidney transplant, which saved the lives of three patients. Six surgical procedures, four at Swedish and two at OHSU, involving more than 30 medical professionals were performed in a single day.

The paired exchange is the result of a regional partnership between Swedish, Virginia Mason, Sacred Heart Medical Center in Spokane and Oregon Health & Science University. The organizations are participating in a clinical trial, sponsored by BiologicTx, to examine how regional paired exchange may improve kidney transplant rates for patients in the Northwest.

Swedish Ballard Opens Level II Nursery

April 24, 2015

SEATTLE, April 24, 2015 — Swedish Ballard will open a new Level II Nursery on Monday, April 27. The Level II Nursery allows for premature babies— born as early as 34 weeks gestational age — to receive specialized, around-the-clock care from a trained team of experts.

Premature babies often face health challenges that require special interventions such as feeding support, intravenous therapy or supplemental oxygen. Previously, infants born at Swedish Ballard who needed specialized neonatal care were transferred to other area hospitals. With the new Level II Nursery, these infants can remain at Swedish Ballard with their families.

Swedish Ballard Receives Pathway to Excellence Designation

April 23, 2015

First hospital in Washington state to earn this honor

We are excited to announce that Swedish Ballard has received the Pathway to Excellence® designation from the American Nurses Credentialing Center (ANCC), making it the first hospital in Washington state to earn this honor.

The Pathway to Excellence® program recognizes health care and long-term care organizations for positive practice environments where nurses excel. To qualify, organizations must meet 12 Pathway Practice Standards essential to an ideal nursing practice environment.

Swedish Cancer Institute Elevates Personalized Medicine Program with Innovative Software Platform

April 23, 2015

The adoption of Syapse Precision Medicine Platform will help deliver large-scale genomic and clinical data to enhance patient care

SEATTLE, April 23, 2015 – The Swedish Cancer Institute (SCI), one of the Northwest’s leading cancer treatment centers, announced today the adoption of Syapse Precision Medicine Platform to enhance its Personalized Medicine Program. The innovative software platform will enable clinicians to better integrate genomic information into patient care and move critical cancer research forward.

The Personalized Medicine Program, launched in April 2014, combines advanced treatments based on the “molecular fingerprint” of a tumor with individualized emotional and physical supportive care. SCI’s gene alteration panel, developed in partnership with CellNetix Pathology & Laboratories, is based on a focused set of gene alterations that are most relevant to cancer treatments. By combining gene alteration data with the clinical decision support of the Syapse platform, patients may receive tailored therapies or targeted clinical trials specific to their molecular fingerprint instead of treatments based solely on the origin of their cancer.

Swedish Issaquah Announces High-Level Containment Assessment Unit

April 22, 2015

As efforts continue in West Africa to control the current Ebola outbreak, the CDC has prompted US healthcare facilities to implement systems necessary to raise preparedness levels at home. The lessons learned from the few cases of US infection have been well utilized in planning and preparing for such events, and Swedish Issaquah is pleased to announce the arrival of its own modular high-level assessment and isolation unit.

In November 2014 Swedish set the goal of being among the first hospitals in Washington to be designated as Ebola assessment-ready, and after an extensive multidisciplinary effort on the part of nearly every provider and volunteer, that designation is confirmed. The program, organized in coordination with state and federal officials, utilizes the hospital’s existing Airborne Infection Isolation Rooms and introduces strict protocols for admissions screening and triage.

Swedish Epilepsy Center Recognized as Level 4 Epilepsy Center by NAEC

April 16, 2015

The National Association of Epilepsy Centers (NAEC) recognized the Swedish Epilepsy Center as a Level 4 Epilepsy Center, a testament to the comprehensive, specialized care Swedish provides for patients with epilepsy.

Level 4 Epilepsy Centers have the professional expertise and facilities to provide the highest-level medical and surgical evaluation and treatment for patients with complex epilepsy. The accreditation, awarded April 1, 2015, renewed the Center’s Level 4 status.

Swedish Named Official Medical Sponsor of the Seattle Reign FC

April 01, 2015

SEATTLE – April 1, 2015 — Swedish has been designated by the Seattle Reign Football Club (FC) as the official medical services sponsor of the professional women’s soccer team.

“We’re thrilled to have the opportunity to not only cheer for the team when they are on the field, but we also get to work with the athletes and trainers to keep the players in peak physical condition,” said Andrew J. Cole, MD, executive director of musculoskeletal services at Swedish.

Becker's Hospital Review Names Swedish Medical Group a 2015 Great Place to Work in Healthcare

March 27, 2015

Swedish Medical Group (SMG) has been named among the “150 Great Places to Work in Healthcare” on Becker’s Hospital Review’s 2015 list. SMG was the only medical group located in Washington to be included on the list.

Each year, Becker's Hospital Review develops this list through nominations and editorial research, and 150 organizations are chosen for their robust benefits, wellness initiatives, commitment to diversity and inclusion, professional development opportunities and work environments that promote employee satisfaction and work-life balance.

Swedish Cancer Institute Recognized by the Commission on Cancer for Outstanding Achievement in 2014

March 25, 2015

The Commission on Cancer (CoC) recognized Swedish Cancer Institute with the 2014 Outstanding Achievement Award. Swedish is among the top 15 percent of the cancer programs surveyed by the CoC. Swedish is also the only Seattle-area health system to receive this recognition during 2014.

“This recognition by the Commission on Cancer is a testament to the sustained excellence in patient-centered care delivered by the teams of professionals at the Swedish Cancer Institute,” said Thomas, Brown, MD, executive director of the Swedish Cancer Institute.

Viewing Page 5 of 7 | Showing Results 41 - 50 of 62